𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation

✍ Scribed by Dr. C. Shustik; R. Mick; R. Silver; A. Sawitsky; K. Rai; L. Shapiro

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
376 KB
Volume
6
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

The effect of early therapy on the course of chronic lymphocytic leukemia (CLL) has not been established. Fifty-nine patients with indolent Rai stage I and II CLL were randomized to receive intermittent chlorambucil once a month or to receive no treatment. The two groups were comparable in entry characteristics. At 5 years from randomization there was no significant difference in survival between the two groups although the proportion of patients exhibiting active disease 5 years after randomization is 70 per cent in the untreated group and 55 per cent in the treated group. In this study, early treatment of CLL with intermittent chlorambucil did not result in a survival advantage for patients with indolent stage I and II CLL.

πŸ“œ SIMILAR VOLUMES

A pilot study of epirubicin and chloramb
A pilot study of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL)
✍ Dr G. M. Smith; J. A. Child; D. W. Milligan; M. A. McEvoy; J. A. Murray πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 428 KB

In a pilot study of the combination of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL), 10 patients with advanced or progressive disease were treated in four centres. Up to a total of 15 courses in individual patients were given. Toxicity was relatively mild with n

Treatment of chronic lymphocytic leukemi
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone
✍ Emilio Montserrat; Antonio AlcalΓ‘; Ricardo Parody; Andreu Domingo; Javier GarcΓ­a πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 685 KB

Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednime (PDN) (60 mg/m2 orally, days 1-5) every 2 weeks or cyclophosphamide (600 mg/

Early treatment of high-risk chronic lym
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
✍ Clive S. Zent; Timothy G. Call; Tait D. Shanafelt; Renee C. Tschumper; Diane F. πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract ## BACKGROUND. Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors of a high risk of disease progression, together with the development of newer, more targeted therapies, could change this para